**MHRA**
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

**gov.uk/mhra**

# Decision Cover Letter

## Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan and to the deferral

MHRA-100157-PIP01-21-M01

# Scope of the Application

## Active Substance(s)

EXENATIDE

## Condition(s)

Type 2 diabetes mellitus

## Pharmaceutical Form(s)

Solution for injection; Powder and solvent for prolonged-release suspension for injection; Solution for injection in pre-filled pen

## Route(s) of Administration

Subcutaneous use

## Name / Corporate name of the PIP applicant

AstraZeneca UK Limited

## Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, AstraZeneca UK Limited submitted to the licensing authority on 30/09/2021 16:23 BST an application for a Modification

The procedure started on 18/11/2021 11:55 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

**gov.uk/mhra**

# Final Decision Letter

MHRA-100157-PIP01-21-M01

Of 13/12/2021 13:09 GMT

On the adopted decision for EXENATIDE (MHRA-100157-PIP01-21-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for EXENATIDE, Solution for injection; Powder and solvent for prolonged-release suspension for injection; Solution for injection in pre-filled pen , Subcutaneous use .

This decision is addressed to AstraZeneca UK Limited, 600 Capability Green, Luton, United Kingdom, LU1 3LU

# ANNEX I

## 1. Waiver

### 1.1 Condition:

| |
|---|
| Treatment of Type 2 diabetes mellitus The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 10 years of age Pharmaceutical form(s): Solution for injection; Solution for injection in pre-filled pen; Powder and solvent for prolonged-release suspension for injection Route(s) of administration: Subcutaneous use Reason for granting waiver: on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s). |

## 2. Paediatric Investigation Plan:

### 2.1 Condition(s):

| |
|---|
| Treatment of Type 2 Diabetes Mellitus |

## 2.2 Indication(s) targeted by the PIP:

Non-Insulin dependent diabetes mellitus (treatment including thiazolidinediones) Non-Insulin dependent diabetes mellitus - in combination with insulin (with or without oral antidiabetics) Non-Insulin dependent diabetes mellitus (excluding treatment with thiazolidinediones)

## 2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 10 years to less than 18 years of age

## 2.4 Pharmaceutical Form(s):

Solution for injection; Solution for injection in pre-filled pen; Powder and solvent for prolonged-release suspension for injection

## 2.5 Studies:

| Study Type | Number of Studies | Study Description |
|---|---|---|
| **Quality Measures** | 0 | Not applicable |
| **Non-Clinical Studies** | 2 | Study 1 Juvenile toxicity study in male rats to investigate potential effects of Bydureon on sexual maturation Study 2 Juvenile toxicity study in female rats to investigate potential effects of Bydureon on sexual maturation. |
| **Clinical Studies** | 3 | Study 3 Randomised, single-blind, dose-escalating, placebo-controlled crossover study to evaluate the pharmacokinetics, pharmacodynamics and tolerability of exenatide in adolescent patients with type 2 diabetes mellitus (2993-124) Study 4 Double-blind, placebo-controlled, randomized, multi-center parallel study of the safety and efficacy of exenatide twice daily (as monotherapy and adjunctive therapy to oral antidiabetic agents) in children and adolescents with type 2 diabetes mellitus (H8O-MC-GWBQ) Study 5 Double-blind, placebo-controlled, randomized, multi-center parallel study of the safety and efficacy of exenatide once weekly (bydureon), as monotherapy and adjunctive therapy to oral antidiabetic agents and/or insulin, in children and |

| | | |
|---|---|---|
| | | adolescents with type 2 diabetes mellitus. |
| **Extrapolation, Modeling & Simulation Studies** | 0 | Study 6: Study deleted during EMEA-000689-PIP01-09-M06<br>Study 7: deleted in modification MHRA-100157-PIP01-21-M01<br>Study 8: Study deleted during EMEA-000689-PIP01-09-M06<br>Study 9: Study deleted during EMEA-000689-PIP01-09-M07. |
| **Other Studies** | 0 | Not applicable |
| **Other Measures** | 0 | Not applicable |

### 3. Follow-up, completion and deferral of a PIP:

| | |
|---|---|
| **Concerns on potential long term safety and efficacy issues in relation to paediatric use:** | Yes |
| **Date of completion of the paediatric investigation plan:** | 31/12/2020 |
| **Deferral of one or more studies contained in the paediatric investigation plan:** | Yes |